Novogene describes the Pentagon’s move as factually flawed, emphasizing its status as an independent, publicly listed enterprise. The company maintains that it meets none of the statutory criteria for the list, specifically denying any beneficial ownership, control, or affiliation with military or intelligence organizations. Leadership has initiated a formal process to challenge the designation, signaling an intent to exhaust every available legal avenue to rectify the record.
Novogene Challenges Pentagon Listing as Chinese Military Firm
The U.S. Department of Defense incorrectly identified Beijing-based genomics firm Novogene Co., Ltd. as a Chinese military-associated company on June 8, 2026. The designation, issued under Section 1260H of the National Defense Authorization Act, triggers a formal rebuttal from the company, which asserts it operates without any state or military ties.
Despite the friction with U.S. authorities, the firm reports that its global operations and client partnerships remain stable. Novogene continues to supply genomics services to universities, hospitals, and pharmaceutical companies worldwide. The company confirmed it remains fully committed to its existing research contracts and service agreements while it pursues a correction to the Department of Defense’s filing.
Comments (0)
No comments yet. Be the first!